Faro AI closed a $37.3 million Series B led by Merck Global Health Innovation Fund and S32, with participation from existing backers General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital and Zetta, plus new investor Ankona Capital.
The company's core insight is structural. While competitors deploy large language models to parse clinical documents, Faro built proprietary ontologies that translate the interconnected scientific, medical, regulatory and operational decisions in drug development into machine-readable intent. That distinction matters: AI agents that reason across a standardized data model can automate workflows with context and governance, not just surface-level pattern matching.
The market validation is concrete. Six of the world's ten largest pharmaceutical companies now use Faro's platform to model development programs across therapeutic areas and study designs, automating everything from clinical protocol design to regulatory document generation and risk identification. That breadth of adoption at scale suggests the company has solved a real workflow problem, not built a niche tool.
Faro's competitive moat sits in those proprietary data models—the translation layer between messy clinical reality and executable software. That moat gets deeper with each customer deployment, as the company accumulates domain-specific training data that rivals can't easily replicate. The business model rewards both penetration (more workflows automated per customer) and expansion (moving into new therapeutic areas and study designs).
The capital will fund deeper customer deployments and expansion across drug development lifecycles, from first-in-human studies through regulatory approval. For Merck—which also runs a venture arm—the investment signals internal confidence that AI-driven automation will reshape how pharma allocates R&D spend.
